| abstract |
The present invention relates to compounds represented by formula (I); where D represents the dehydrogenated residue of a drug containing hydroxyl groups or the hydrogenated residue of a drug containing NH acid functional groups; the substituents present in the alpha and beta phenyl nucleus are either in the meta- or para-position relative to each other; and the phenyl ring may further be substituted; m is equal to the integer 0 or 1, p is equal to the integer 0 or 1; n represents an integer between 1 and 4; R1 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, a group having the formula -COOR5 where R5 represents an alkyl or aralkyl group, or a group carbamoyl having the formula -CONR6R7, where R6 and R7 are identical or different and represent a hydrogen, an alkyl group or together form, with the adjacent nitrogen atom, a heterocyclic ring with 4, 5, 6 or 7 elements; R2 represents hydrogen or an alkyl group; R3 and R4 are the same or different and represent hydrogen or alkyl, aralkyl, alkenyl or cycloalkyl optionally substituted; or R3 and R4 are combined so that -NR3R4 forms a heterocyclic ring with 4, 5, 6 or 7 optionally substituted elements, which, in addition to the nitrogen atom, may contain one or two other heteroatoms chosen from nitrogen, oxygen and sulfur; provided that m is equal to 0 when D represents the dehydrogenated residue of a medicament containing hydroxyl groups, and that m is equal to 1 when D represents the dehydrogenated residue of a medicament containing NH-functional groups; as well as the acid addition salts or the pharmaceutically acceptable quaternary ammonium salts of said compounds. |